Announced Fri, 14 Aug · 09:38 IST
US FDA issues Warning Letter to Aurobindo Pharma subsidiary's Unit I
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.2%1-day move
₹1663.40
prior close
₹1665.60
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.8-2.0-2.1-2.1-2.2-1.1-2.3-3.3-2.5-2.7-0.7-0.2——
Up moveDown movePending
AI summary
Aurobindo Pharma's wholly owned subsidiary Eugia Pharma Specialities' Unit I has received a Warning Letter from the US FDA, following an earlier Official Action Indicated (OAI) status flagged in May 2026. The company clarified there is no impact on existing supplies to US markets. Unit I contributes about 2 percent to the company's overall group revenue. The company said it will work closely with the US FDA to enhance compliance.
Likely market impact
Limited near-term impact since the unit is only 2 percent of revenue and US supplies continue, but the Warning Letter may weigh on sentiment and future approvals.